Obesity and female reproductive health


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To analyze the medical and civilized social aspects of obesity and its significance for the development and aggravation of impairments in the female reproductive system. Material and methods. Scientific information sources on the pathogenesis of metabolic disturbances associated with obesity and its impact on the female reproductive system are reviewed; current approaches to hormone therapy in obese women were considered. Results. The theoretical and clinical aspects confirming the relationship between adipose tissue metabolism and impairments in the female reproductive system are described. Weight-loss recommendations (regimens and drug therapy) are given. Conclusion. Weight reduction regimens and drug therapy provide a means of using the protective effects of estrogen-gestagen contraceptives and reducing the risk of cardiovascular events.

Full Text

Restricted Access

About the authors

Natalia V. Aganezova

I.I. Mechnikov North-Western State Medical University

Email: aganezova@mail.ru
MD, Associate Professor, Department of Obstetrics and Gynecology

Sergey S. Aganezov

I.I. Mechnikov North-Western State Medical University

Email: aganezov@mail.ru
PhD, Associate Professor, Department of Obstetrics and Gynecology

References

  1. Дедов И.И., Мельниченко Г.А., Фадеев В.Ф. Эндокринология. Учебник. 2-е изд. М.: ГЭОТАР-Медиа; 2013. 328с. [Dedov I.I., Melnichenko G.A., Fadeev V.F. Endocrinology. Textbook. 2nd ed. Moscow: GEOTAR Media; 2013. 328p. (in Russian)]
  2. AMA American Medical Association (AMA) 2013 Annual Meeting. Medscape Medical News. June 19, 2013. Available at: www.medscape.com/ viewarticle/806566
  3. World Health Organization (WHO). International classification of diseases and related health problems. Geneva: WHO; 1994.
  4. Информационный бюллетень ВОЗ № 311, январь 2015 г. Available at: www. who.int/mediacentre/factsheets/fs311/ru/ [WHO Media centre Obesity and overweight Fact sheet N 311 Updated January 2015]
  5. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000; 11(8): 327-32.
  6. Garaulet M. Chronobiology and obesity: the orchestra out of tune. Clin. Lipidol. 2010; 5(2): 181-8.
  7. Taheri S., Lin S., Austin D., Young T., Mignot E. Short sleep duration is associated with reduce leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004; 1(3): e62.
  8. Knutson K.L., Spiegel K., Penev P., Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Med. Rev. 2007; 11(3): 163-78.
  9. Van Cauter E., Holmback U., Knutson K., Leproult R., Miller A., Nedeltcheva A. et al. Impact of sleep and sleep loss on neuroendocrine and metabolic function. Horm. Res. 2007; 67(Suppl. 1): 2-9.
  10. Soltani Z., Washco V., Morse S., Reisin E. The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. Curr. Hypertens. Rep. 2015; 17: 7. doi: 10.1007/s11906-014-0520-2.
  11. Caprio M., Zennaro M.C., Fève B., Mammi C., Fabbri A., Rosano G. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor. Climacteric. 2008; 11(3): 258-64.
  12. Репина М.А., Кузьмина-Крутецкая С.Р. Метаболический синдром у женщин. Методические рекомендации. Айламазян Э.К., ред. СПб.: Издательство Н-Л; 2011. 45с. [Repin M.A., Kuzmina-Krutetskaya S.R. Metabolic syndrome in women. Guidelines. Ailamazyan E.K., ed. St. Petersburg: Publisher N-L; 2011. 45p. (in Russian)]
  13. Консенсус Экспертов по междисциплинарному подходу к ведению, диагностике и лечению больных с метаболическим синдромом. Кардиоваскулярная терапия и профилактика. 2013; 12(6): 41-81. [The expert consensus on an interdisciplinary approach to the management, diagnosis and treatment of patients with metabolic syndrome. Kardiovaskulyarnaya terapiya i profilaktika. 2013; 12 (6): 41-81. (in Russian)]
  14. Alberti K.G., Zimmet P.Z., Shaw J. Metabolic syndrome- a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 2006; 23(5): 469-80.
  15. Белоцерковцева Л.Д., Коваленко Л.В., Корнеева Е.В., Майер Ю.И., Шишанок О.Ю., Ерченко Е.Н. Особенности метаболического синдрома у женщин в различные периоды жизни: патогенез, клиника, диагностика, лечение. Учебное пособие. М.: Академия Естествознания; 2010. 73с. [Belotserkovtseva L.D., Kovalenko L.V., Korneeva E.V., Mayer Yu.I., Shishanok O.Yu., Erchenko E.N. Features of the metabolic syndrome in women in different periods of life: pathogenesis, clinical features, diagnosis, treatment. Tutorial. Moscow: Academy of Natural Sciences; 2010. 73c. (in Russian)]
  16. Jayagopal V., Kilpatrick E.S., Jennings P.E., Hepburn D.A., Atkin S.L. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J. Clin. Endocrinol. Metab. 2003; 88(4): 1528-33.
  17. Tomlinson J.A., Pinkney J.H., Evans P., Millward A., Stenhouse E. Screening for diabetes and cardiometabolic disease in women with polycystic ovary syndrome. Br.J. Diabet. Vasc. Dis. 2013; 13(3): 115-23.
  18. Синдром поликистозных яичников в репродуктивном возрасте (Современные подходы к диагностике и лечению). Клинические рекомендации (протоколе лечения) Министерства здравоохранения Российской Федерации. М.; 2015. 28с. [Polycystic ovary syndrome in reproductive age (Modern approaches to diagnostics and treatment). Clinical guidelines (treatment protocol), the Ministry of Health of the Russian Federation. Moscow; 2015. 28p. (in Russian)]
  19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 19-25.
  20. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565-92. doi: 10.1210/jc.2013-2350.
  21. Fauser B.C., Tarlatzis B.C., Rebar R.W., Legro R.S., Balen A.H., Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 2012; 97(1): 28-38. e25.
  22. ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Hum. Reprod. Update. 2012; 18(5): 586-99.
  23. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции. ВОЗ, 4 издание, 2009». М.; 2012. [National medical eligibility criteria of contraceptive methods. Adapted from the document „Medical Eligibility Criteria of acceptability of the use of contraceptive methods. WHO, 4th edition, 2009”. Moscow; 2012. (in Russian)]
  24. Department of Reproductive Health, World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015. PMID: 26447268.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies